CatalystCorporate

LIGAND PHARMACEUTICALS ( LGND ): MASSIVE XOMA ACQUISITION DOUBLES THE ROYALTY BOOK

Xoma acquisition doubles Ligand's royalty book, signaling major corporate expansion.

What changed

Xoma acquisition doubles Ligand's royalty book, signaling major corporate expansion.

Why it matters

Xoma acquisition doubles Ligand's royalty book, signaling major corporate expansion. — impact context not separately stored; see What changed.

Sources